Cytokeratin 18‐based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients

Waidmann, Oliver; Brunner, Friederike; Herrmann, Eva; Zeuzem, Stefan; Piiper, Albrecht; Kronenberger, Bernd

doi:10.1111/liv.13117

Cited by 16 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sekiguchi et al [44] detected M30, M65, and M65EpiDeath in 130 PBC patients and found that they were all significantly higher in PBC than in healthy controls and were significantly correlated with fibrosis stage; the mortality was significantly higher in patients with high M65EpiDeath levels (HR: 6.13). Waidmann et al [45] prospectively investigated 211 LC patients and found that these three CK-18-based cell death markers also could be potential biomarkers of severity of LC induced by other etiologies (mainly alcohol abuse and HCV infection), but only M65EpiDeath was associated with the patients prognosis, and interestingly, M65EpiDeath level was a factor for mortality in patients with compensated LC (HR: 11.483), but not decompensated LC.…”

Section: Prognostic Biomarkers Of Survival Ratementioning

confidence: 99%

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Chen

Wan

Wang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Liver cirrhosis is the terminal stage of most chronic liver conditions, with a high risk of mortality. Careful evaluation of the prognosis of cirrhotic patients and providing precise management are crucial to reduce the risk of mortality. Although the liver biopsy and hepatic venous pressure gradient (HVPG) can efficiently evaluate the prognosis of cirrhotic patients, their application is limited due to the invasion procedures. Child-Pugh score and the model for end-stage liver disease (MELD) score had been widely used in the assessment of cirrhotic prognosis, but the defects of subjective variable application in Child-Pugh score and unsuitability to all phases of liver cirrhosis in MELD score limit their prognostic values. In recent years, continuous efforts have been made to investigate the prognostic value of body fluid biomarkers for cirrhotic patients, and promising results have been reported. Since the collection of fluid specimens is easy, noninvasive, and repeatable, fluid biomarkers can be ideal indicators to predict the prognosis of cirrhosis. Here, we reviewed noninvasive fluid biomarkers in different prognostic functions, including the prediction of survival and complication development.

show abstract

Section: Prognostic Biomarkers Of Survival Ratementioning

confidence: 99%

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Chen

Wan

Wang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The intra-and inter assay variation were below 20 percent. Markers of cell death, namely M30 and M65 and macrophage activation, namely soluble CD163, were measured as described previously [23][24][25].…”

Section: Elisa Measurementsmentioning

confidence: 99%

Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis

et al. 2018

View full text Add to dashboard Cite

“…Waidmann et al found that ALT and AST strongly related to CK‐18 levels, also related to the indicator of the liver‐related functional ability to hold bilirubin and inversely with albumin. Serum CK‐18 levels increase with disease severity (Child‐Pugh, MELD score).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of serum cytokeratin‐18 in children with chronic liver disease

Shalby

Ibrahim

Behairy

et al. 2019

J Paediatrics Child Health

View full text Add to dashboard Cite

EgyptAim: This study aimed to assess the diagnostic value of serum cytokeratin-18 in children with chronic liver diseases (CLD) and correlate its serum level with liver histology and other liver biomarkers. Methods: This study included two groups, the first group included children with CLD and the second group included healthy matched age and gender subjects as a control group, complete history and clinical examination, and serum CK-18 was measured using the sandwich enzyme-linked immunosorbent assay technique. Results: Serum concentrations of CK-18 were significantly elevated in CLD patients with mean AE standard deviation (1070.63 AE 699.2 ng/mL) compared to healthy controls mean AE standard deviation (203.95 AE 83.57 ng/mL). CK-18 levels were associated with a change in hepatocyte and portal tract (P = 0.005) as it was elevated with cirrhosis and fibrosis stage (P = 0.02) as it was elevated with moderate and severe fibrosis than mild fibrosis, also it showed a gradual increase in accordance with child Pugh score. There was a positive correlation between CK-18 levels and Total IgG, paediatric end-stage liver disease score and model for end-stage liver disease scores, the best cutoff point of CK-18 was 624 ng/mL, with sensitivity 93.06%, specificity 62.5% and diagnostic accuracy 90.0% for detection of fibrosis. Conclusion: CK-18 could be used as a non-invasive diagnostic marker in children with CLD.

show abstract

Cytokeratin 18‐based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients

Abstract: Epithelial cell death reflected by M65EpiDeath serum levels is an indicator for the severity of cirrhosis and a prognostic survival parameter in cirrhotic patients.

Cited by 16 publications

References 34 publications

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis

Diagnostic value of serum cytokeratin‐18 in children with chronic liver disease

Contact Info

Product

Resources

About